Progressive disease after ABMT for Hodgkin's disease.

Bolwell, B J; Kalaycio, M; Goormastic, M; Dannley, R; Andresen, S W; Lichtin, A; Overmoyer, B; Pohlman, B

Bolwell, B J; Kalaycio, M; Goormastic, M; Dannley, R; Andresen, S W; Lichtin, A; Overmoyer, B; Pohlman, B.

Affiliation

Bolwell BJ; Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH, USA.

Bone Marrow Transplant ; 20(9): 761-5, 1997 Nov.

Article in En | MEDLINE | ID: mdl-9384478

Subject(s)

Hematopoietic Stem Cell Transplantation; Hodgkin Disease/therapy; Adult; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carmustine/therapeutic use; Cyclophosphamide/therapeutic use; Disease-Free Survival; Etoposide/therapeutic use; Female; Humans; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Hematopoietic Stem Cell Transplantation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 1997 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links